Bruce, Justine

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet

Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 3,336

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer

McHugh, D., Eisenberger, M., Heath, E. I., Bruce, J., Danila, D. C., Rathkopf, D. E., Feldman, J., Slovin, S. F., Anand, B., Chu, R., et al. (2019) · Investigational New Drugs

Prostate Cancer Treatment and ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 23